ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) saw a significant decrease in short interest in January. As of January 31st, there was short interest totalling 129,600 shares, a decrease of 53.2% from the January 15th total of 276,800 shares. Approximately 5.5% of the shares of the stock are short sold. Based on an average daily volume of 836,000 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Investors Weigh In On ZyVersa Therapeutics

An institutional investor recently bought a new position in ZyVersa Therapeutics stock. Virtu Financial LLC bought a new stake in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 25,259 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned 1.08% of ZyVersa Therapeutics at the end of the most recent quarter. 3.91% of the stock is currently owned by institutional investors.

ZyVersa Therapeutics Stock Down 0.8 %

NASDAQ:ZVSA opened at $1.30 on Friday. ZyVersa Therapeutics has a one year low of $0.98 and a one year high of $25.00. The stock has a 50 day moving average price of $1.25 and a 200 day moving average price of $1.91.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.